EWA
LXRX icon

EverSource Wealth Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

EverSource Wealth Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75 Sell
48
-110
-70% -$160 ﹤0.01% 4296
2025
Q4 		$182 Sell
158
-297
-65% -$408 ﹤0.01% 4038
2025
Q3 		$615 Sell
455
-708
-61% -$804 ﹤0.01% 3899
2025
Q2 		$1.1K Buy
1,163
+233
+25% +$151 ﹤0.01% 3707
2025
Q1 		$429 Buy
930
+898
+2,806% +$567 ﹤0.01% 3505
2024
Q4 		$24 Buy
+32
New +$39 ﹤0.01% 3697

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

EverSource Wealth Advisors's LXRX Position: Q1 2026 in Review

EverSource Wealth Advisors reduced its Lexicon Pharmaceuticals (LXRX) stake by 70% in Q1 2026, selling an estimated $160 and leaving 48 shares worth $75. The position accounts for ﹤0.01% of the portfolio, ranked #4296.

EverSource Wealth Advisors first reported a position in LXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.1K in Q2 2025. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • EverSource Wealth Advisors held 48 shares of Lexicon Pharmaceuticals worth $75 as of Q1 2026.
  • EverSource Wealth Advisors sold 110 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $160.
  • Lexicon Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #4296 holding.
  • EverSource Wealth Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • EverSource Wealth Advisors's Lexicon Pharmaceuticals position peaked at $1.1K in Q2 2025.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.